At baseline, T2DM patients had an overgrowth of intestinal mycetes, increased intestinal permeability (measured by elevated fecal zonulin concentration), systemic low-grade inflammation (measured by CRP), and decreased insulin sensitivity (determined via the homeostatic model assessment of insulin resistance (HOMA-IR) index). The gene discussed is CRP; the disease is type 2 diabetes mellitus.